Table 4 Mean (SD) of groups who did (YES) and did not (NO) receive further botulinum toxin-A, mean (SD) difference within groups, and mean (95% CI) difference between groups for all outcomes
Outcome | Groups | Difference within groups | Difference between groups | ||||
|---|---|---|---|---|---|---|---|
Month 0 | Month 12 | Month 12 minus Month 0 | Month 12 minus Month 0 | ||||
YES (n = 35) | NO (n = 105) | YES (n = 35) | NO (n = 98) | YES | NO | YES minus NO | |
Goal attainment GAS (T-score) | N/A | N/A | 38 (11) | 42 (15) | N/A | N/A | -5 (-10 to 1) |
Upper limb activity BBT (blocks/s) | 0.03 (0.07) | 0.03 (0.09) | 0.03 (0.08) | 0.05 (0.12) | 0.00 (0.04) | 0.01 (0.06) | -0.01 (-0.03 to 0.01) |
Spasticity Tardieu Scale (0–4) | 1.9 (0.8) | 2.0 (0.8) | 1.5 (0.7) n = 12 | 1.5 (0.7) n = 33 | -0.3 (1.1) | -0.5 (0.8) | 0.3 (-0.3 to 0.8) |
Wrist extension ROM (deg) | 29 (40) | 39 (34) | 30 (35) | 25 (37) | 0 (30) | -14 (27) | 14 (3 to 25) |
Grip strength MVC dynamometry (kg) | 5.5 (5.5) | 3.7 (5.0) | 4.4 (5.2) | 3.8 (4.7) | -1.0 (4.1) | 0.5 (3.7) | -1.5 (-3.0 to 0.0) |
Pain 10-cm VAS (0–10) | 1.0 (1.8) | 2.2 (2.8) | 0.7 (1.2) | 1.2 (2.2) | -0.4 (2.1) | -0.9 (2.6) | 0.6 (-0.4 to 1.5) |
Burden of care CBS (0–16) | 6.6 (3.3) | 6.6 (4.0) | 4.5 (3.6) | 4.4 (4.0) | -2.0 (3.8) | -2.3 (4.4) | 0.3 (-1.6 to 2.2) |
Quality of life, EQ-5D Overall health (0 to 100) | 60 (22) | 64 (20) | 66 (24) | 66 (23) | 6 (24) | 2 (21) | 4 (-5 to 12) |